To elucidate the mechanism of insulin's anticatabolic effect in humans, protein dynamics were evaluated in the wholebody, splanchnic, and leg tissues in six C-peptide-negative type I diabetic male patients in the insulin-deprived and insulin-treated states using two separate amino acid models (leucine and phenylalanine). L-(1-3C,'5N)leucine, L-(ring-2H5)phenylalanine, and L-(ring-2H2) tyrosine were infused intravenously, and isotopic enrichments of [1-3C, 5N]-leucine, (13C)leucine, ("3C)ketoisocaproate, (2H5)phenylalanine, [21H4] tyrosine, (2H2)tyrosine, and '3CO2 were measured in arterial, hepatic vein, and femoral vein samples.
Introduction
Patients with type I diabetes (IDDM)' typically were cachectic during the preinsulin era (1) . This changed after the introduc-tion of insulin therapy. Insulin treatment decreased urinary nitrogen loss (2) , increased lean body mass (3) , and decreased concentrations of circulating amino acids, especially those of branched amino acids (4, 5) . Insulin also controlled the energy expenditure to normal (6) . These are generally described as insulin's anticatabolic effect. Numerous investigators had sought to understand the mechanism of insulin's anticatabolic effect on protein (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . These studies are reviewed elsewhere (18) . A common conclusion of these studies is that insulin decreases whole-body protein breakdown in the fasted state. This insulin effect has been shown to be partially due to the effect on skeletal muscle (20, 21) , although this is contradicted by some studies (13, (22) (23) (24) . Insulin's effect on protein breakdown in other regions, such as splanchnic tissues, has not been investigated. The splanchnic region is a major site of protein metabolism (25) , but its precise role remains to be clearly defined.
Insulin also has been shown to reduce the rate of leucine oxidation (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , although it is unclear whether this is related to changes in leucine transamination or due to increased oxidation of ketoisocaproate (KIC), the transamination product of leucine. Unlike the inhibitory effect of insulin on protein breakdown and leucine oxidation, insulin's effect on protein synthesis in the fasted state remains controversial.
It was initially reported that in the insulin-deprived state, IDDM patients have increased nonoxidative leucine disposal, indicating an increased whole-body protein synthesis (7, 8) . Insulin infusion in these patients decreased whole-body protein synthesis (10, (12) (13) (14) (15) (16) . These results were in conflict with the existing view that insulin promotes protein synthesis (26, 27) . This view was based on strong in vitro evidence documenting insulin's stimulatory effect on protein synthesis (26, 27) . The in vitro data are supported by studies in growing rats rendered diabetic by streptozotocin (28, 29) . However, unlike the growing rats, human studies have been performed in adult diabetic patients. These studies consistently show either a significant increase (7, 8, (10) (11) (12) (13) (14) (15) (16) or slight but not statistically significant increase of whole-body protein synthesis in insulin-deprived IDDM patients (9, 17) . Additional studies in IDDM patients (8, 15, 17, 18) and in normal subjects (20) (21) (22) demonstrated that these changes in protein synthesis do not occur in the muscle protein. It was proposed that in the insulin-deprived state, increased flux of amino acids from protein breakdown increases protein synthesis in relatively insulin-insensitive tissues, such as gut and liver (18) . We tested the hypothesis that increased whole-body protein synthesis occurs in insulindeprived IDDM patients because of an increase in the synthesis rate of proteins in insulin-insensitive tissues, such as in gut and liver. Consequently, we studied IDDM patients to determine the effect of insulin treatment on protein synthesis and degradation in the splanchnic region and determined whole-body and skeletal muscle protein dynamics. The protocol was submitted to and approved by the institution ethics committee. The nature, purpose, and possible risks involved in the study were carefully explained to each subject before his informed consent was obtained.
Subjects
Six male IDDM patients participated in the study. The individual clinical characteristics are given in Table I . Four patients had background retinopathy (microaneurysm), and one had microalbuminuria. All patients had normal serum creatinine values. Except for insulin, the patients had no other medication. All patients were treated with four daily insulin injections (regular insulin before meals and intermediate acting insulin at bedtime). Subjects whose insulin requirements were > 70 units per day were excluded in order to avoid patients with severe insulin resistance.
Study protocol
Two separate studies were performed on each subject at 2-3-wk interval. One study was performed in the insulin-deprived state and another in the insulin-treated state. In three subjects, studies in the insulindeprived state were done first, and in the other three patients, studies in the insulin-treated state were done first. The patients were admitted to the hospital on the day before the study. The last subcutaneous injection of regular insulin was given at 6:00 PM. At 9:00 PM in the evening before the study, an intravenous insulin infusion was started to maintain a blood glucose level between 4 and 6 mmol/liter until 7:00 AM in the morning of the study day (insulin treatment). For the other study, saline instead of insulin was infused intravenously from midnight of the day before the study until the end of the study (insulin deprivation). The studies were performed after an overnight fast; ingestion of water was allowed. In the case of the studies performed in the insulintreated state, the insulin dose was adjusted from 7:00 AM every 10-15 min on the basis of blood glucose values in order to maintain blood glucose at a steady state of 4.4±0.4 mmol/liter (see Fig. 1 ).
In both studies, a forearm vein was cannulated for infusions. Catheters were then placed in the brachial artery, femoral artery, femoral vein, and hepatic vein as was previously described (25, 30) . Hepatic vein catheters were inserted under fluoroscopic guidance, and placement was performed as reported previously (30) . The femoral artery line was used for infusing indocyanine green dye at a rate of 0.6 mg/min in order to measure blood flow in the leg and splanchnic regions using indicator dye dilution techniques (30, 31) . Branchial artery, femoral vein, and hepatic vein lines were used to collect blood samples.
After taking triplicate baseline breath samples and blood samples from arterial, femoral vein, and hepatic vein lines, priming doses of L-( 1-3C,'5N)leucine (6.8 ymol/kg), L-(ring-2H5)phenylalanine (4.6 Amol/kg), L-(ring-2H2)tyrosine (3.5 qmol/kg), L-(ring-2H4)tyrosine (1.5 jsmol/kg), and (13C)sodium bicarbonate (0.2 mg/kg) were given in order to prime the respective pools for achieving an early plateau.
A continuous infusion of L-( 1-3C,15N)leucine (7.5 Amol/kg/h), L-(2H5)phenylalanine (4.6 ('3C)KIC in plasma was determined as its quinoxalinol-TMS derivative under electron ionization conditions using an HP5971A gas chromatograph/mass spectrometer, and the enrichment was monitored using ions m/z 233/232 (33) (34) (35) . KIC concentration was measured using ketovaleric acid as an internal standard.
Blood 13Co2 enrichment and '3C02 in the breath samples in an isotope ratio mass spectrometry were as previously described (36 Substrate concentration. Plasma concentrations of amino acids were determined by an HPLC system (HP 1090 series 2 HPLC, 1046 fluorescence detector and cooling system) with precolumn O-phthalaldehyde derivatization (37) . Glucose was analyzed by an enzymatic technique using a glucose analyzer (Beckman Instr., Inc., Fullerton, CA); lactate (38) , free fatty acid (39) , and 3-hydroxybutyrate (40) were measured as previously described.
Hormonal assays. Plasma concentrations of free insulin (41), glucagon (42) , growth hormone (43), IGF-I (44), IGF-I-binding protein-1 (45) epi-and norepinephrine (46) , and cortisol were measured by a radioimmunoassay technique.
Calculations. For all calculations of amino acid kinetics, mean values of isotopic enrichments at all nine time points were used.
Leucine kinetics Leucine carbon flux (Q.) and leucine nitrogen fluxes (Qn) were measured by tracer dilution techniques as previously described (7, 32) .
, in which i is the rate of tracer infusion of (jimol/kg/h), and Ei and Ep are enrichment of the tracer infused and plasma enrichment of the tracer at isotopic plateau, respectively. Leucine oxidation (C) was measured using ( 13C) KIC as the precursor pool (47) . Nonoxidative leucine flux, an estimation of leucine incorporated into protein (protein synthesis), was computed by subtracting leucine oxidation from leucine carbon flux, since the leucine carboxyl group is either irreversibly lost as CO2 or incorporated into protein. Leg and splanchnic region. Leucine kinetics, leucine appearance from protein breakdown (protein to leucine), the component of leucine disappearance not accounted for by leucine oxidation, and leucine transamination (leucine to protein or protein synthesis) in the leg and splanchnic region were measured using the equations previously described by Cheng et al. (36) .
Phenylalanine kinetics
Phenylalanine is not oxidized or transaminated in the periphery but is degraded in the liver through tyrosine (20, 21, (48) (49) (50) . It is therefore assumed that in the splanchnic region, phenylalanine is either converted to tyrosine or incorporated into protein. In leg tissues, the only fate of phenylalanine is its incorporation into protein.
Whole body. For whole body measurements of phenylalanine kinetics, the equations described by Thompson et al. (34) were used. Phenylalanine flux (QP) and tyrosine flux (QT) were calculated by isotope dilution in the same way leucine flux was calculated. The rate of phenylalanine conversion to tyrosine (IPT) was calculated as follows:
where [2H4] TyrEj and [2H5] PheEj are the isotopic enrichments of the respective tracers in plasma, and Ip is the infusion rate of (2H5)phenylalanine (jimol/kg/h).
Phenylalanine incorporation into protein (Sp) for whole body is calculated by simply subtracting IPT from QP, since phenylalanine is irreversibly lost either by its degradative pathway via its conversion into tyrosine or by incorporation into protein (21, 51) .
Splanchnic region. Phenylalanine appearance rate (Rp) in the postabsorptive state can be calculated by the following equation (the details of its derivation have been previously described for an arterio-venous study across leg [51] 
where [2H5] PheEA and [2H5] PheEv represent isotopic enrichments on the arterial and venous sides, respectively, F is plasma flow, and PheA is the phenylalanine concentration on the arterial side.
In these equations it is assumed that phenylalanine is not directly oxidized in the splanchnic region but is degraded via tyrosine, and its only degradative pathway is via its conversion into tyrosine. The precursor pool for protein synthesis and phenylalanine conversion to tyrosine are assumed to be represented by hepatic vein amino acid enrichment. Since phenylalanine entering the splanchnic bed has only two fatesincorporation into protein and conversion into tyrosine-at steady state, the following is true:
in which Sp is phenylalanine incorporation into protein (or protein synthesis), Ip is phenylalanine conversion to tyrosine, PheA 1) . Leg blood flow was higher during insulin deprivation than during insulin treatment (P < 0.01; Table H ). However, splanchnic blood flow did not differ among studies (Table II) . Splanchnic and leg exchange (arterial minus venous multiplied by blood flow) of glucose, glycerol, and lactate was higher during the insulin-deprived state than during the insulin-treated state (P < 0.01), whereas the difference in glycerol exchange from the leg did not reach statistical significance between the two studies. Plasma concentrations (mean of three measurements of each hormone) during the last 60 min are given in Table m . Plasma concentrations of free insulin (P < 0.01) and IGF-I (P < 0.05) were higher during the insulin-treated state than during the insu- Amino acids Plasma concentrations of amino acids are given in Table IV , and amino acid balance (i.e., arterial concentrations minus venous concentrations multiplied by blood flow) are given in Table V . In the case of amino acid balance, we included the measurements using gas chromatograph/mass spectrometer (using internal standards) for leucine, KIC, phenylalanine, and tyrosine because they were used for calculating protein dynamics. Plasma concentrations of histidine, glycine, alanine, phenylalanine, isoleucine, leucine, and valine were reduced by insulin treatment (P < 0.01). Whole-blood amino acid concentrations demonstrated a similar trend (data not shown). Amino acid balance across the splanchnic region and leg are given in Table V . Both plasma amino acid balance and blood amino acid balance were performed. The conclusions were the same, and therefore only plasma balance is given in Table V . Balance across the leg of aspartate, serine, histidine, glycine, threonine, alanine, tyrosine, methionine, phenylalanine, isoleucine, leucine, lysine, and KIC was significantly higher during insulin deprivation than during insulin treatment, indicating an insulin-induced fall in net amino acid output from the Isotopic plateau Plasma isotopic enrichments of KIC and CO2 leucine are given in Fig. 2 , and isotopic enrichments of phenylalanine and tyrosine are given in Fig. 3 . Isotopic plateau was achieved during this period, since the slopes of these isotopic enrichments did not differ from 0. Plasma concentrations of leucine, KIC, phenylalanine, and tyrosine are given in Fig. 4 , and they achieved a plateau during the study period because the slopes of these measurements were not significantly different from 0. Whole-body protein dynamics Leucine kinetics (Fig. 5) Phenylalanine kinetics in the splanchnic region (Fig. 8) Phenylalanine kinetics across the leg (Fig. 8) . Phenylalanine appearance rate from protein (protein breakdown) (5.0±0.7 vs. 3.2±0.5 1tmol/min, P < 0.05) was higher during insulin deprivation than during insulin treatment. There was no difference in phenylalanine incorporation into protein (2.46±0.6 vs. 2.37±4) in the two studies.
Discussion
The most important finding from this study is that in IDDM patients, protein synthesis in the splanchnic region is elevated during insulin deprivation and this increase accounts for the entire increment in whole-body protein synthesis based on the phenylalanine model (Fig. 9) model. Whereas insulin reduced this elevated protein synthesis in the splanchnic region, it had no effect on protein synthesis in the leg (skeletal muscle). Insulin reduced protein breakdown not only in the splanchnic region, but also in the leg (skeletal muscle). The fall in protein breakdown in the splanchnic region occurred in conjunction with a fall in protein synthesis, such that it did not result in a net positive protein balance. The improvement of protein conservation by insulin appears to be entirely due to the fall in protein breakdown in skeletal muscle and in other tissues (exclusive of the splanchnic region). A substantial acceleration in leucine transamination was noted during the insulin-deprived state. We also confirmed the previously reported inhibition of the leucine oxidation rate by insulin. It was, however, noted that insulin increased the oxidation of KIC.
Two separate amino acid models were applied to study protein metabolism simultaneously in the whole body, as well as in the leg and splanchnic regions, in the diabetic patients. The leucine model was previously used in whole-body and forearm studies (32, 36) , but here is applied for the first time in splanchnic studies. In addition, we used double-labeled leucine to study leucine C and N metabolism simultaneously in the leg and splanchnic regions in IDDM patients. The phenylalanine model has been previously used in forearm and leg studies in humans (20, 21, 51) . The application of the phenylalanine model is simpler in the leg, since the only fate of phenylalanine in the leg is its incorporation into protein. But unlike in the leg, phenylalanine is also converted to tyrosine in the liver. We therefore measured the conversion rate of phenylalanine to tyrosine in the splanchnic region, which allowed us to estimate phenylalanine 2932 K. S. Nair, G. C. Ford, K Ekberg, E. Fernqvist-Forbes, and J. Wahren Figure 5 . Whole-body leucine kinetics. Leucine carbon flux (LEU CFlux) (P < 0.05), leucine oxidation (Leu Oxid) (P < 0.05), leucine incorporation into protein (Leu to Prot) (P < 0.01), leucine nitrogen flux (Leu N Flux) (P < 0.001), KIC transamination from leucine (KIC to Leu) (P < 0.001), and leucine transamination from KIC (Leu to KIC) (P < 0.001) are all significantly higher during insulin treatment than during insulin deprivation.
protein metabolism in the splanchnic region is limited, this model may provide new insight into the regulation of protein turnover in humans. The correct identification of the precursor pools for transamination, oxidation, and protein synthesis and the pool into which protein breakdown occurs is critical for the accuracy of the measurements reported in this paper. Since the immediate precursor of leucine oxidation is KIC, we used KIC as the precursor of leucine oxidation measurements. For measurements of protein breakdown and leucine oxidation in a tissue, its intracellular isotopic enrichment should be ideally determined, which is not practical in human studies such as ours. All calculations across the tissue beds were performed using venous blood. This was based on an assumption that enrichment within venous blood more closely represents intracellular isotopic enrichment than that within arterial blood. This supposition is supported by studies in animals (52, 53) which show that venous isotopic enrichment closely approximates intracellular isotopic enrichments within the liver and muscle. A problem inherent to all human studies is the difficulty in measuring aminoacyl-tRNA (the obligatory precursor of protein synthesis [54] Figure 6 . Whole-body phenylalanine and tyrosine kinetics. Phenylalanine flux (PHE Flux) (P < 0.01), phenylalanine incorporation into protein (PHE to PROTEIN) (P < 0.01), and tyrosine flux (TYR Flux) (P < 0.01) were significantly higher during insulin deprivation than during insulin treatment, whereas phenylalanine conversion to tyrosine (PHE to TYR) was not different.
not significantly different from the phenylalanyl-tRNA enrichment in the respective tissues (52) . Similarly, our study (52) and that of Watt et al. (55) demonstrated that muscle leucyltRNA enrichment is closely approximated by plasma (13C) KIC enrichment and the enrichment within interstitial fluid obtained by muscle biopsy. To our knowledge, this is the first time that protein synthesis and degradation rates in the splanchnic region of diabetic patients have been measured. In a previous study on normal subjects, L-( 1-14C) leucine was used to measure leucine kinetics in leg and splanchnic tissues (49) . Animal studies indicated that in streptozotocin-induced diabetic rats, gut protein content increased whereas skeletal muscle protein content decreased (27, 28) . This increase in gut protein may be related to hyperphagia, but the increase in gut protein content occurred in the presence of insulin deficiency in these animals. Gut protein synthesis was found to be relatively insensitive to insulin (27, 28 protein synthesis (56, 57) . Insulin also has been reported to stimulate albumin synthesis rate while inhibiting the synthesis rate of fibrinogen in humans (58) although another group found no such effect of insulin (59) . Based on both animal and in vitro studies, it is reasonable to say that liver protein synthesis is also relatively insensitive to insulin. We therefore hypothesized that during the insulin-deficiency state, an increased amino acid availability due to protein breakdown stimulated protein synthesis primarily in insulin-insensitive tissues such as the gut and some proteins in the liver ( 18) . The current results provide support for this hypothesis. Both systemic (22) and intraarterial infusions of insulin (20, 21) have been shown to inhibit skeletal muscle protein breakdown in human. In some studies systemic infusion of insulin decreased whole-body protein breakdown but failed to decrease skeletal muscle protein breakdown (13, 23, 24) . The current study used much smaller doses of insulin than other studies. Unlike the previous studies, we only infused insulin sufficient to maintain euglycemia. Insulin at this concentration (12 1U/ml) was sufficient to cause a significant decrease in skeletal muscle protein breakdown. In fact, our study suggests that insulin's protein anabolic effect is largely due to its inhibition of protein breakdown in skeletal muscle. It has been shown that the maximal inhibitory effect of insulin on skeletal muscle protein breakdown in humans occurs at a low insulin concentration and that there is no dose-related fall in skeletal muscle protein breakdown (20) . In our subjects, the fall in protein breakdown occurred with a small dose of insulin because our subjects were insulin deficient. An increase in insulin concentrations achieved by other studies may not have shown a decrease in skeletal muscle proteins breakdown because the maximal effect may have already been achieved by the circulating insulin concentration.
The current study further confirmed previous report by us (15, 18) and others ( 17, (20) (21) (22) 60 motes muscle protein synthesis (26) (27) (28) (29) probably by its effect at the posttranscriptional level (26, 27) . Recently, it has been reported that the insulin-induced stimulation of muscle protein synthesis takes place only in growing rats and not in fully grown rats (50) . It is possible that insulin may have a different effect in children with IDDM than in adult diabetic subjects. It was recently reported that in an 1 1-y-old girl with congenital lipodystrophy and diabetes, insulin stimulated whole-body protein synthesis in addition to reducing protein breakdown (61) . It has been hypothesized that the lack of effect of insulin on protein synthesis in the postabsorptive state is due to the reduced supply of amino acids (secondary to insulin-induced inhibition of protein breakdown) in the fasted human subjects (8, 10, 18, 24) . Infusion of amino acids simultaneously with insulin has been reported to stimulate protein synthesis in some (14) but not in all studies (17, 62) . Additional studies are needed to resolve these contradictory results.
Analysis of the phenylalanine data indicates that the change in whole-body protein synthesis (-600 1Lmol/h) can be fully (100%) accounted for by the changes within the splanchnic bed (Fig. 9) . Based on the leucine model, 82% of the change in whole-body protein synthesis is accounted for by the splanchnic region. Insulin deprivation caused a net uptake of phenylalanine within the splanchnic bed, and a net release of phenylalanine from the leg. The latter indicates that insulin deprivation results in skeletal muscle but not splanchnic catabolism. In the insulindeprived state, using the phenylalanine model, splanchnic regions account for 50% of the whole-body protein synthesis rate, whereas skeletal muscle accounts for only 19%. In the insulintreated state, splanchnic regions contribute only 34% to wholebody protein synthesis, whereas the skeletal muscle contribution increased to 27%. This proportion of contribution by skeletal muscle to whole-body protein synthesis is similar to what has been observed in normal healthy subjects (18) , whereas the observed contribution in the insulin-deprived state is lower than that in normal subjects. Leucine data also showed comparable changes. In the insulin-deprived state, increased uptake of amino acids (not only glycogenic, but also other amino acids) occurred in the splanchnic region presumably for protein synthesis. The increased flux of amino acids from skeletal muscle and other tissues might stimulate protein synthesis in splanchnic regions. This process helps to conserve amino acids in the insulin-deprived state and thus contributes to the survival of the patients during insulin deprivation. A substantial increase in leucine transamination occurred during insulin deprivation. It is noteworthy that a higher percentage of KIC transaminated from leucine was oxidized during insulin treatment than during insulin deprivation (Table VI) . The cause of enhanced transamination during insulin deprivation is unknown. One possibility is that of glucagon activation of branched-chain 2-oxo acid dehydrogenase (63). Against this, however, is the fact that glucagon receptors have not been demonstrated in skeletal muscle, in which there is a greater part of this enzyme activity.
In conclusion, this study demonstrated that increased protein synthesis occurs in the splanchnic bed during insulin deprivation and that this increased protein synthesis accounts for the increment of whole-body protein synthesis that occurs in insulindeprived IDDM patients. We also observed a substantial increase in leucine transamination during insulin deprivation, which is responsible for the increased KIC oxidation in these patients.
